This article is more than 5 years old. Information may no longer be current.

Teva launches cyclosporine ophthalmic emulsion in Canada

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Teva Canada Ltd. announced the launch of Teva-Cyclosporine ophthalmic emulsion, 0.05%, a twice-daily eye drop used in the treatment of dry eye.

The subsidiary of Teva Pharmaceutical Industries Ltd. stated in a press release that cyclosporine ophthalmic emulsion is indicated for treating moderate to moderately severe aqueous-deficient dry eye disease characterized by moderate to moderately severe ocular staining, reduction in tear production and fluctuating visual symptoms, such as blurred vision.

Teva said that the drop is approved by Health Canada and is available immediately to pharmacies across Canada.

“The launch of Teva-Cyclosporine demonstrates Teva Canada's research and development capabilities and desire to continue to support niche patient groups, utilizing specialized technology,” the company said in the release.